文献速递胸部肿瘤

荷兰手术切除的T3N0非小细胞肺癌基于TNM-7和TNM-8定义的人群结局研究:对分期变更的论证及将组织学纳入分期算法的建议

A Population-Based Study of Outcomes in Surgically Resected T3N0 Non-Small Cell Lung Cancer in The Netherlands, Defined Using TNM-7 and TNM-8; Justification of Changes and an Argument to Incorporate Histology in the Staging Algorithm.
PubMed 文献 · J Thorac Oncol · 2018-11-05

该研究基于荷兰全国登记数据,纳入2010至2013年按TNM第7版分期为pT3N0M0且接受手术的非小细胞肺癌患者683例,按pT3亚组分析总生存。结果显示肿瘤直径大于7 cm亚组与胸膜侵犯亚组生存相近,混合组生存较差,两个或以上结节亚组中腺癌生存显著优于鳞状细胞癌。作者认为组织学类型在两个或以上结节亚组中是有意义的描述符,不支持将直径大于7 cm组迁移至pT4,而混合组值得迁移至pT4。

要点

  • 肿瘤直径大于7 cm亚组3年和5年总生存率分别为59.9%和47.2%,与胸膜侵犯亚组的50.4%和45.3%相近。
  • 混合组3年和5年总生存率分别为37.5%和28.7%,与国际肺癌研究协会数据库中TNM第8版IIIB期和pT4病例的结局相近。
  • 两个或以上结节亚组中腺癌5年总生存率65.1%显著优于鳞状细胞癌的47.2%(p < 0.001)。

核心结论

  • 该基于人群的pT3N0非小细胞肺癌总生存分析提示组织学类型在两个或以上结节亚组中是有意义的描述符。
  • 研究结果不支持将肿瘤直径大于7 cm组迁移至TNM第8版分类的pT4。
  • 研究结果提示两个pT3描述符的组合(混合组)值得迁移至pT4。

研究设计与样本

  • 从荷兰综合癌症组织检索2010至2013年按TNM第7版分期为pT3N0M0并接受手术的非小细胞肺癌患者资料,并与全国登记处的相应病理数据匹配。
  • 共683例患者符合分析条件,分为四个主要pT3亚组:肿瘤直径大于7 cm、同一肺叶内分离肿瘤结节(两个或以上结节)、脏层胸膜侵犯和混合组(主要由肿瘤直径大于7 cm合并脏层胸膜侵犯组成)。

主要发现

  • 肿瘤直径大于7 cm亚组3年和5年总生存率分别为59.9%和47.2%,与胸膜侵犯亚组的50.4%和45.3%相近。
  • 混合组3年和5年总生存率分别为37.5%和28.7%,与国际肺癌研究协会数据库中TNM第8版IIIB期和pT4病例的结局相近。
  • 两个或以上结节亚组3年和5年总生存率分别为70.6%和62.8%。
  • 两个或以上结节亚组中腺癌患者5年总生存率65.1%显著优于鳞状细胞癌患者的47.2%(p < 0.001)。
  • 腺癌亚组的预后可能与pT2类别相当,而鳞状细胞癌结节可保持为pT3。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective was to study outcomes in patients in a population registry who were surgically staged as having pT3N0 NSCLC according to the seventh and eighth editions of the TNM staging classification. METHODS: Details of patients who underwent surgery for NSCLC staged as pT3N0M0 from 2010 to 2013 on the basis of the seventh edition of the TNM classification were retrieved from the Netherlands Comprehensive Cancer Organization. These data were next matched with corresponding pathology data from a nationwide registry. Patients were categorized into four major pT3 subgroups as follows: those with a tumor diameter more than 7 cm, those with separate tumor nodules in the same lobe (two or more nodules), those with parietal pleural invasion, and a mixed group (consisting mainly of those with a tumor diameter larger than 7 cm combined with parietal pleural invasion). RESULTS: A total of 683 patients were eligible for analysis. The 3- and 5-year overall survival (OS) rates for the subtype tumor diameter larger than 7 cm were 59.9% and 47.2%, respectively, and were comparable to the rates for the subtype with pleural invasion (50.4% and 45.3%), respectively. The mixed group had worse 3- and 5-year OS rates (37.5% and 28.7%, respectively), which were comparable to the outcomes for TNM eighth edition-staged IIIB and pT4 cases in the International Association for the Study of Lung Cancer database. For the subtype two or more nodules, the 3- and 5-year OS rates were 70.6% and 62.8%, respectively, with patients with adenocarcinoma showing a significantly better OS than did patients with squamous cell carcinoma: a 5-year OS rate of 65.1% versus 47.2%, respectively (p < 0.001), suggesting that the prognosis for the adenocarcinoma subgroup may be comparable to that for the pT2 category, whereas squamous cell carcinoma nodules can remain pT3. CONCLUSION: This population analysis of overall survival rate by pT3N0 subcategory for NSCLC suggests that histologic type is a relevant descriptor in the category two or more nodules. The findings do not support migration of the group with a tumor diameter larger than 7 cm to the category pT4in the eighth edition of the TNM classification, and they suggest that a combination of two pT3 descriptors (the mixed group) merits migration to pT4.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Blaauwgeers H, Damhuis R, Lissenberg-Witte BI, et al. A Population-Based Study of Outcomes in Surgically Resected T3N0 Non-Small Cell Lung Cancer in The Netherlands, Defined Using TNM-7 and TNM-8; Justification of Changes and an Argument to Incorporate Histology in the Staging Algorithm. J Thorac Oncol. 2018. PMID: 30408568. doi:10.1016/j.jtho.2018.10.164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。